Intra-tumor injection study for stomach and esophagus cancer with ARID1a mutation
Treatments studied
Part of Cancer clinical trials.
This trial tests a new approach where immune cells are injected directly into the tumor in people with a specific genetic change (ARID1a mutation) in their stomach or esophagus cancer. It aims to see if this treatment can help when used before any other cancer therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is in the stomach or esophagus and has an ARID1a gene change (found by a blood or tumor test).
- Your cancer has not spread to other parts of the body (non-metastatic) and is either locally advanced or cannot be removed with surgery.
- You have not had any previous treatment for this cancer (like chemotherapy or radiation).
- Your tumor is MSI-stable or pMMR (a type of tumor that does not have high mutation levels).
- You are 18 years or older and weigh more than 66 pounds.
- You are able and willing to have a biopsy (tissue sample) taken from your tumor.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of gene therapy (OBP-301) injected directly into the tumor, combined with the immunotherapy drug Keytruda (pembrolizumab), for people with advanced stomach, junction, or esophageal cancer. Researchers want to see if this combination can help when standard treatments have stopped working.
This Phase 1 trial tests how well a tailored (response-adapted) chemotherapy plan works before surgery for stomach or gastroesophageal junction cancer. It aims to improve treatment planning while checking early safety.
This trial tests a combination of adebrelimab (an immunotherapy) with either two other experimental drugs (SHR-A1811 or SHR-A1904) plus chemotherapy, or another drug (SHR-8068), as a first treatment for gastric or gastroesophageal junction adenocarcinoma. It aims to find if these combos work better than standard care.
This trial tests whether adding the cholesterol drug simvastatin to standard immunotherapy and chemotherapy can help people with a specific type of gastroesophageal cancer (ARID1A mutated, HER2 negative). It is for patients who have not had prior treatment for advanced disease.
This trial tests a combination of immunotherapy (a treatment that helps your immune system fight cancer) with radiation therapy for a certain type of stomach or gastroesophageal junction cancer that has a special genetic marker. The goal is to see if this combination is safe and effective.
This trial is testing a combination of immunotherapy, anti-angiogenic (blood vessel blocker) therapy, and chemotherapy for people with advanced stomach or gastroesophageal junction cancer that hasn't spread yet. It is for those whose tumors have a low PD-L1 score and who haven't had treatment for the advanced cancer before.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.